Clinical Trial Update: A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease [Phase 2]

View source ↗

Summary

An open-label Phase 2 study assesses long-term therapy with tofacitinib (CP-690,550) over 48 weeks in Crohn's disease; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-10-16